Navigation Links
As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
Date:2/23/2009

Percentage of Clinicians Performing hsCRP Testing Will Increase Dramatically Over the Next Six Months, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, as a result of the JUPITER clinical trial, 65 percent of surveyed managed care organizations' (MCO) pharmacy directors say they will reimburse AstraZeneca's Crestor for healthy patients with elevated levels of high sensitivity C-reactive protein (hsCRP). The JUPITER trial enrolled apparently healthy subjects without high LDL cholesterol but with elevated hsCRP and randomized subjects to receive Crestor or placebo. Trial data showed a 44 percent reduction in major cardiovascular events and reduced all-cause mortality by 20 percent among participants receiving Crestor.

The new Physician & Payer Forum report entitled The JUPITER Trial: Will Physicians and Payers Support a Change in Statin Prescribing? finds that 15 percent of surveyed MCO pharmacy directors will grant Crestor more favorable tier status in light of the trial. Crestor is currently on tier one of only 10 percent of surveyed MCO private health plans, while Pfizer's Lipitor is on tier one of 30 percent of surveyed MCO plans. Additionally, among Medicare prescription drug plans, Crestor has the highest rate of coverage among branded statins.

"Our findings suggest that in response to the JUPITER trial data, many clinicians will start using a statin ahead of diet and exercise changes," said Decision Resources Analyst Graeme Green, Ph.D. "Most of these clinicians will favor Crestor for these patients, indicating that AstraZeneca will benefit the most from such a trend."

The report finds that, in response to JUPITER trial data, the percentage of clinicians performing hsCRP testing will increase dramatically over the next six months among patients with and without cardiovascular risk factors. Surveyed clinicians anticipate that the percentage of patients with no cardiovascular risk factors tested for elevated hsCRP will increase from 5 percent in July 2008, to 26 percent in July 2009. The percentage of patients with two or more cardiovascular risk factors tested by primary care physicians for hsCRP will increase from 16 percent in July 2008 to 40 percent in July 2009.

The JUPITER Trial: Will Physicians and Payers Support a Change in Statin Prescribing? is based on a U.S. survey of 71 primary care physicians, 72 cardiologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                           Decision Resources, Inc.
    Christopher Comfort                          Elizabeth Marshall
    781-296-2597                                 781-296-2563
    ccomfort@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
2. XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress
3. Insulet Corporation to Report Fourth Quarter and Full Year 2008 Financial Results on Thursday, March 5, 2009
4. WebMD Announces Fourth Quarter Financial Results
5. Medarex to Announce 2008 Fourth Quarter and Year-End Financial Results on Wednesday, February 25, 2009
6. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
7. HLTH Corporation Announces Fourth Quarter Financial Results
8. NuVasive Announces Web Cast and Conference Call of Fourth Quarter 2008 Results
9. Webcast Alert: Usinas Siderurgicas de Minas Gerais S.A. - USIMINAS Announces Fourth Quarter 2008 Earnings Results Webcast
10. QLT Announces Fourth Quarter and Year End 2008 Results
11. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... India , June 24, 2016 ... Needles Market by Type (Standard Pen Needles, Safety Pen ... Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, ... by MarketsandMarkets, This report studies the market for the ... expected to reach USD 2.81 Billion by 2021 from ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: